BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hochstatter KR, Stockman LJ, Holzmacher R, Greer J, Seal DW, Taylor QA, Gill EK, Westergaard RP. The continuum of hepatitis C care for criminal justice involved adults in the DAA era: a retrospective cohort study demonstrating limited treatment uptake and inconsistent linkage to community-based care. Health Justice 2017;5:10. [PMID: 29086078 DOI: 10.1186/s40352-017-0055-0] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 4.6] [Reference Citation Analysis]
Number Citing Articles
1 Rosati S, Wong A, Marco VD, Pérez-hernandez P, Macedo G, Brixko C, Ranieri R, Campanale F, Basciá A, Fernández-rodríguez C, Lédinghen VD, Maida I, Teti E, Mangia A, Vanstraelen K, Hernández C, Mertens M, Ntalla I, Ramroth H, Jiménez E. Real-world effectiveness of sofosbuvir/velpatasvir for the treatment of hepatitis C virus in prison settings. Future Virology 2022;17:419-28. [DOI: 10.2217/fvl-2022-0016] [Reference Citation Analysis]
2 Jacka BP, Bazerman LB, Dickerson C, Moody M, Martin J, Patry E, Cady T, Compere H, Boudreau M, Beckwith CG. Feasibility of hepatitis C virus testing and linkage in community supervision offices: Great potential but persistent challenges. International Journal of Drug Policy 2022;103:103668. [DOI: 10.1016/j.drugpo.2022.103668] [Reference Citation Analysis]
3 Hale AJ, Mathur S, Dejace J, Lidofsky SD. Statewide Assessment of the Hepatitis C Virus Care Cascade for Incarcerated Persons in Vermont. Public Health Rep 2022;:333549221077070. [PMID: 35264027 DOI: 10.1177/00333549221077070] [Reference Citation Analysis]
4 Moore MS, Bocour A. Association Between Time to First RNA-Negative Test Result Among People With Hepatitis C Virus Infection and Homelessness or Testing at a Correctional or Substance Use Treatment Facility, New York City. Public Health Rep 2021;:333549211049263. [PMID: 34694921 DOI: 10.1177/00333549211049263] [Reference Citation Analysis]
5 Hariri S, Alavi M, Roshandel G, Mohammadi Z, Fazel A, Amiriani T, Bazazan A, Motamed-Gorji N, Sohrabpour A, Merat S, Poustchi H, Malekzadeh R. An intervention to increase hepatitis C virus diagnosis and treatment uptake among people in custody in Iran. Int J Drug Policy 2021;95:103269. [PMID: 33991887 DOI: 10.1016/j.drugpo.2021.103269] [Reference Citation Analysis]
6 Wong YJ, Thurairajah PH, Kumar R, Fock KM, Law NM, Chong SY, Manejero FG, Ang TL, Teo EK, Tan J. The impact of unrestricted access to direct-acting antiviral among incarcerated hepatitis C virus-infected patients. Clin Mol Hepatol 2021;27:474-85. [PMID: 33601868 DOI: 10.3350/cmh.2021.0015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Hawks LC, McGinnis KA, Howell BA, Khan MR, Edelman EJ, Justice AC, Wang EA. Frequency and Duration of Incarceration and Mortality Among US Veterans With and Without HIV. J Acquir Immune Defic Syndr 2020;84:220-7. [PMID: 32049771 DOI: 10.1097/QAI.0000000000002325] [Reference Citation Analysis]
8 Hariri S, Sharafi H, Sheikh M, Merat S, Hashemi F, Azimian F, Tamadoni B, Ramazani R, Gouya MM, Abbasi B, Tashakorian M, Alasvand R, Alavian SM, Poustchi H, Malekzadeh R. Continuum of hepatitis C care cascade in prison and following release in the direct-acting antivirals era. Harm Reduct J 2020;17:80. [PMID: 33081794 DOI: 10.1186/s12954-020-00431-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
9 Chan J, Kaba F, Schwartz J, Bocour A, Akiyama MJ, Rosner Z, Winters A, Yang P, MacDonald R. The hepatitis C virus care cascade in the New York City jail system during the direct acting antiviral treatment era, 2014-2017. EClinicalMedicine 2020;27:100567. [PMID: 33150329 DOI: 10.1016/j.eclinm.2020.100567] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Yang TH, Fang YJ, Hsu SJ, Lee JY, Chiu MC, Yu JJ, Kuo CC, Chen CH. Microelimination of Chronic Hepatitis C by Universal Screening Plus Direct-Acting Antivirals for Incarcerated Persons in Taiwan. Open Forum Infect Dis. 2020;7:ofaa301. [PMID: 32818142 DOI: 10.1093/ofid/ofaa301] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
11 Chan J, Schwartz J, Kaba F, Bocour A, Akiyama MJ, Hobstetter L, Rosner Z, Winters A, Yang P, MacDonald R. Outcomes of Hepatitis C Virus Treatment in the New York City Jail Population: Successes and Challenges Facing Scale up of Care. Open Forum Infect Dis 2020;7:ofaa263. [PMID: 33123613 DOI: 10.1093/ofid/ofaa263] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
12 Biondi MJ, Feld JJ. Hepatitis C models of care: approaches to elimination. CanLivJ 2020;3:165-76. [DOI: 10.3138/canlivj.2019-0002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
13 Biondi MJ, Feld JJ. Hepatitis C models of care: approaches to elimination. CanLivJ 2020;3:165-76. [DOI: 10.3138/canlivj-2019-0002] [Reference Citation Analysis]
14 Godin A, Kronfli N, Cox J, Alary M, Maheu-Giroux M. The role of prison-based interventions for hepatitis C virus (HCV) micro-elimination among people who inject drugs in Montréal, Canada. Int J Drug Policy 2021;88:102738. [PMID: 32278651 DOI: 10.1016/j.drugpo.2020.102738] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
15 Li H, Cameron B, Douglas D, Stapleton S, Cheguelman G, Butler T, Luciani F, Lloyd AR. Incident hepatitis B virus infection and immunisation uptake in Australian prison inmates. Vaccine 2020;38:3255-60. [PMID: 32151462 DOI: 10.1016/j.vaccine.2020.02.076] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Kronfli N, Dussault C, Klein MB, Lebouché B, Sebastiani G, Cox J. The hepatitis C virus cascade of care in a Quebec provincial prison: a retrospective cohort study. CMAJ Open 2019;7:E674-9. [PMID: 31796509 DOI: 10.9778/cmajo.20190068] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
17 Kronfli N, Buxton JA, Jennings L, Kouyoumdjian F, Wong A. Hepatitis C virus (HCV) care in Canadian correctional facilities: Where are we and where do we need to be? CanLivJ 2019;2:171-83. [DOI: 10.3138/canlivj.2019-0007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
18 Lazarus JV, Pericàs JM, Picchio C, Cernosa J, Hoekstra M, Luhmann N, Maticic M, Read P, Robinson EM, Dillon JF. We know DAAs work, so now what? Simplifying models of care to enhance the hepatitis C cascade. J Intern Med 2019;286:503-25. [PMID: 31472002 DOI: 10.1111/joim.12972] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 11.7] [Reference Citation Analysis]
19 Overton K, Clegg J, Pekin F, Wood J, Mcgrath C, Lloyd A, Post JJ. Outcomes of a nurse-led model of care for hepatitis C assessment and treatment with direct-acting antivirals in the custodial setting. International Journal of Drug Policy 2019;72:123-8. [DOI: 10.1016/j.drugpo.2019.02.013] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
20 Abe CM, Aguwa M, Zhao M, Sullivan J, Porsa E, Nijhawan AE. Hepatitis C Virus Infection in the Dallas County Jail: Implications for Screening, Prevention, and Linkage to Care. Public Health Rep 2019;134:626-33. [PMID: 31530093 DOI: 10.1177/0033354919874081] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
21 Kronfli N, Nitulescu R, Cox J, Moodie EE, Wong A, Cooper C, Gill J, Walmsley S, Martel-Laferrière V, Hull MW, Klein MB; Canadian Co-Infection Cohort Study. Previous incarceration impacts access to hepatitis C virus (HCV) treatment among HIV-HCV co-infected patients in Canada. J Int AIDS Soc 2018;21:e25197. [PMID: 30460791 DOI: 10.1002/jia2.25197] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
22 Grebely J, Hajarizadeh B, Lazarus JV, Bruneau J, Treloar C; International Network on Hepatitis in Substance Users. Elimination of hepatitis C virus infection among people who use drugs: Ensuring equitable access to prevention, treatment, and care for all. Int J Drug Policy 2019;72:1-10. [PMID: 31345644 DOI: 10.1016/j.drugpo.2019.07.016] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
23 Høj SB, Jacka B, Minoyan N, Artenie AA, Bruneau J. Conceptualising access in the direct-acting antiviral era: An integrated framework to inform research and practice in HCV care for people who inject drugs. Int J Drug Policy 2019;72:11-23. [PMID: 31003825 DOI: 10.1016/j.drugpo.2019.04.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
24 Redman JS, Sterling RK. Treating HCV in a Captive Audience: Eradication Efforts in the Prison Microenvironment. American Journal of Gastroenterology 2018;113:1585-7. [DOI: 10.1038/s41395-018-0201-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
25 Marotta PL, Gilbert L, Terlikbayeva A, Wu E, El-Bassel N. Differences by sex in associations between injection drug risks and drug crime conviction among people who inject drugs in Almaty, Kazakhstan. Int J Drug Policy 2018;60:96-106. [PMID: 30219718 DOI: 10.1016/j.drugpo.2018.07.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
26 Epstein RL, Sabharwal V, Wachman EM, Saia KA, Vellozzi C, Hariri S, Linas BP. Perinatal Transmission of Hepatitis C Virus: Defining the Cascade of Care. J Pediatr 2018; 203: 34-40. e1. [PMID: 30170857 DOI: 10.1016/j.jpeds.2018.07.006] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 6.5] [Reference Citation Analysis]